Faeth Therapeutics, Inc. (FTH) company profile

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company developing multi-node therapies designed to treat various solid tumors. Its primary clinical program is PIKTOR, an investigational all-oral combination of the selective PI3Kα inhibitor serabelisib and the mTORC1 and mTORC2 inhibitor sapanisertib. By simultaneously suppressing multiple points along the oncogenic PI3K/AKT/mTOR signaling pathway, the company seeks to provide deeper and more durable tumor suppression while limiting acquired resistance mechanisms. The candidate targets patients with endometrial cancer and breast cancer, with potential utility extending across tumors regardless of their direct pathway mutational status.

The company operates from its principal executive offices located in Rockville, Maryland. Sensei is currently conducting a Phase 2 clinical trial in second-line advanced endometrial cancer and is advancing a Phase 1b trial in advanced HR-positive and HER2-negative breast cancer, with preclinical and exploratory programs evaluating additional indications in ovarian cancer and genetically defined lung cancer.

Summary of the business section of Faeth Therapeutics's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of March 23, 2026, we had 29 full-time employees, including 23 employees who joined in connection with our acquisition of Faeth.”